TG Therapeutics, Inc. posted a strong Q3 with soaring Briumvi sales and increased guidance. Click for my updated look at TGTX ...

CFO Sean Power stated, "Our third quarter results reflect sustained commercial strength with total revenue reaching $161.7 million, an increase of 93% compared to Q3 '24 and 15% over Q2 '25. Product ...

We recently published a list of 10 Best Performing Growth Stocks in 2025 In this article, we are going to take a look at where TG Therapeutics, Inc. (NASDAQ:TGTX) stands against other best performing ...

The market expects TG Therapeutics (TGTX) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus ...

TG Therapeutics (TGTX) has shared an announcement. At the Company’s 2024 Annual Meeting, stockholders voted to expand the authorized shares of common stock, showcasing active investor participation ...

Total Revenue: $141.1 million for Q2 2025. US Net Product Revenue: $138.8 million, a 91% increase year-over-year. License, Milestone, and Royalty Revenue: $2.3 million for the quarter. Total Operating ...

TG Therapeutics Inc. (NASDAQ:TGTX) shares advanced Wednesday after the biopharmaceutical company announced the completion of a $100 million share repurchase program and unveiled plans for an ...